The specific blockade of the CD155 interaction with multiple inhibitory receptors expressed on NK and T lymphocytes, such as TIGIT, killer-cell immunoglobulin-like receptor (KIR) KIR2DL5 and CD96 [19], is now being explored in various types of cancer [20]. This evidence concerns the gene KIR3DL2 and cancer.